title: Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme.
abstract: The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported. These molecules display enhanced nitric oxide releasing properties due to the presence of an ionisable moiety. The in vivo analgesic/anti-inflammatory activity was maintained in relation to the parent compounds.
authors.affiliation: Dipartimento di Chimica e Tecnologie del Farmaco, Università La Sapienza, Piazzale Aldo Moro 5, I-00185 Roma, Italy. mariangela.biava@uniroma1.it
authors.forename: Mariangela
authors.initials: M
authors.lastname: Biava
authors.forename: Claudio
authors.initials: C
authors.lastname: Battilocchio
authors.forename: Giovanna
authors.initials: G
authors.lastname: Poce
authors.forename: Salvatore
authors.initials: S
authors.lastname: Alfonso
authors.forename: Sara
authors.initials: S
authors.lastname: Consalvi
authors.forename: Giulio Cesare
authors.initials: GC
authors.lastname: Porretta
authors.forename: Silvia
authors.initials: S
authors.lastname: Schenone
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Calderone
authors.forename: Alma
authors.initials: A
authors.lastname: Martelli
authors.forename: Lara
authors.initials: L
authors.lastname: Testai
authors.forename: Carla
authors.initials: C
authors.lastname: Ghelardini
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Di Cesare Mannelli
authors.forename: Lidia
authors.initials: L
authors.lastname: Sautebin
authors.forename: Antonietta
authors.initials: A
authors.lastname: Rossi
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordani
authors.forename: Paola
authors.initials: P
authors.lastname: Patrignani
authors.forename: Maurizio
authors.initials: M
authors.lastname: Anzini
mesh_terms: D019342:Acetic Acid; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D002351:Carrageenan / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003251:Constriction, Pathologic / Q000139:chemically induced / Q000188:drug therapy*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D051379:Mice; D015394:Molecular Structure; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012995:Solubility; D013329:Structure-Activity Relationship
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D009569:Nitric Oxide; D002351:Carrageenan; D051546:Cyclooxygenase 2; D019342:Acetic Acid